|Abstract:||2-Methyl-10-(4-methyl-1-piperazinyl)-4H-thieno-[2,3-b][1,5]benzodiazepine, or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of disorders of the central nervous system. The compound has the following structure: ##STR1##|
|Inventor(s):||Chakrabarti; Jiban K. (Frimley, GB2), Hotten; Terrence M. (Farnborough, GB2), Tupper; David E. (Reading, GB2)|
|Assignee:||Lilly Industries Limited (Basingstoke, GB2)|
Patent Claim Types:|
see list of patent claims
|Compound; Composition; Dosage form; Use; Formulation;|
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|United Kingdom||9009229||Apr 25, 1990|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.